Registration is complimentary and required to attend.
About this webinar:
Return on investment is what drives the persuasion and adoption of innovations in clinical trials.
In this keynote presentation, Kenneth Getz, Tufts Center for the Study of Drug Development, examines research quantifying the short and long term quantitative ROI of DCT deployments and how that can be applicable to the future of clinical trials.
Mr Getz takes the audience through:
- The two methods of gathering return on investment (expected net present value modeling versus benchmark comparisons of performance outcomes)
- When and where each method is being used in today’s more challenging market
- Data gathered from clinical trials on whether or not deploying innovations aided in their speed, quality and cost
- The evolving approaches organizations are implementing to adopt and integrate DCTs into clinical trial planning and execution
This presentation is from the 2024 DPHARM: Disruptive Innovations to Advance Clinical Research meeting.
About DPHARM, the webinar’s associated conference:
DPHARM®: Disruptive Innovations to Advance Clinical Research offers an unparalleled opportunity to hear senior clinical operation executives and innovative thought leaders unveil the latest innovations to modernize clinical trials and reduce patient burden. The concept of DPHARM was founded by Pfizer and Janssen, who continue to play a key role on the steering committee to deliver a highly relevant and engaging program. For more information, visit DPHARMconference.com.
Registration is complimentary and required to attend.
